LY2922470

LY2922470 is a small molecule drug developed as a selective agonist of G protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1). Its primary mechanism of action is to stimulate GPR40, which enhances insulin and glucagon-like peptide-1 (GLP-1) secretion in response to elevated glucose levels. This pharmacological profile makes it a candidate for the treatment of type 2 diabetes mellitus. Preclinical studies have also suggested potential neuroprotective effects in models of ischemic stroke, where LY2922470 reduced infarct size and improved motor function in mice. The drug has been evaluated in phase 1 and phase 2 clinical trials for type 2 diabetes[2][3][4][5].